^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    itareparib (NMS-293)

    i
    Other names: NMS-293, NMS-03305293, NMS-P293, NMS03305293, NMS293, NMSP293, NMS 03305293, NMS 293, NMS P293
    Associations

    News

    Trials
    Company:
    Nerviano Medical Sciences
    Drug class:
    PARP1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    5ms
    Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=10, Recruiting, Nerviano Medical Sciences | Not yet recruiting --> Recruiting
    Enrollment open
    |
    temozolomide • itareparib (NMS-293)
    6ms
    Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer (clinicaltrials.gov)
    P1, N=24, Recruiting, Nerviano Medical Sciences | Not yet recruiting --> Recruiting
    Enrollment open
    |
    topotecan • itareparib (NMS-293)
    6ms
    Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma (clinicaltrials.gov)
    P1/2, N=150, Active, not recruiting, Nerviano Medical Sciences | Trial completion date: Nov 2025 --> Sep 2027 | Trial primary completion date: Jun 2025 --> May 2027
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase) • TERT (Telomerase Reverse Transcriptase)
    |
    EGFR mutation • EGFR amplification • MGMT promoter methylation • IDH wild-type
    |
    temozolomide • itareparib (NMS-293)
    6ms
    Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, Nerviano Medical Sciences | Trial completion date: Nov 2026 --> Feb 2027
    Trial completion date
    |
    temozolomide • itareparib (NMS-293)
    6ms
    Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Nerviano Medical Sciences | Trial completion date: Mar 2027 --> Sep 2027 | Trial primary completion date: Sep 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    topotecan • itareparib (NMS-293)
    10ms
    Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, Nerviano Medical Sciences
    New P1 trial
    |
    temozolomide • itareparib (NMS-293)
    10ms
    Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Nerviano Medical Sciences
    New P1 trial
    |
    topotecan • itareparib (NMS-293)
    10ms
    Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma (clinicaltrials.gov)
    P1/2, N=150, Active, not recruiting, Nerviano Medical Sciences | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase) • TERT (Telomerase Reverse Transcriptase)
    |
    EGFR mutation • EGFR amplification • MGMT promoter methylation • IDH wild-type
    |
    temozolomide • itareparib (NMS-293)
    over1year
    Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=52, Terminated, Nerviano Medical Sciences | N=150 --> 52 | Trial completion date: Dec 2024 --> May 2024 | Active, not recruiting --> Terminated; The study closure is related to sponsor decision to shift towards the clinical development of NMS-03305293 in combination in a broader range of indication and not based on emerging safety or efficacy concerns.
    Enrollment change • Trial completion date • Trial termination • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative • BRCA1 mutation + BRCA2 mutation
    |
    itareparib (NMS-293)
    almost2years
    Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=150, Active, not recruiting, Nerviano Medical Sciences | Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2024
    Enrollment closed • Trial completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative • BRCA1 mutation + BRCA2 mutation
    |
    itareparib (NMS-293)
    almost2years
    Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma (clinicaltrials.gov)
    P1/2, N=150, Recruiting, Nerviano Medical Sciences | N=75 --> 150
    Enrollment change
    |
    EGFR (Epidermal growth factor receptor) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase) • TERT (Telomerase Reverse Transcriptase)
    |
    EGFR mutation • EGFR amplification • MGMT promoter methylation • TERT mutation • IDH wild-type • TERT promoter mutation
    |
    temozolomide • itareparib (NMS-293)
    over2years
    Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma (clinicaltrials.gov)
    P1/2, N=75, Recruiting, Nerviano Medical Sciences | N=125 --> 75
    Enrollment change
    |
    EGFR (Epidermal growth factor receptor) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase) • TERT (Telomerase Reverse Transcriptase)
    |
    EGFR mutation • EGFR amplification • MGMT promoter methylation • TERT mutation • IDH wild-type • TERT promoter mutation
    |
    temozolomide • itareparib (NMS-293)